JINGRUI Holdings (01862): Delay in publishing the performance of the year 2025.
Kaiser Group (01862) announced that in accordance with Listing Rule 13.49(1) and 13.46(2), the company is required to publish a preliminary performance announcement for the financial year ending on December 31, 2025 (2025 annual performance) within three months after the company's fiscal year end (i.e. by March 31, 2026) and to send the corresponding annual report (2025 annual report) to the shareholders within four months after the company's fiscal year end (i.e. by April 30, 2026).
JINGRUI HLDGS (01862) Announcement: According to Rule 13.49(1) and Rule 13.46(2) of the Listing Rules, the Company must publish an announcement on its preliminary results for the financial year ending on 31 March 2026 or before (within three months after the end of the financial year) for the year ended 31 December 2025 (the 2025 annual results). The Company is also required to send the annual report for the year ended 31 December 2025 (the 2025 annual report) to its shareholders within four months after the end of the financial year, on or before 30 April 2026.
The joint and several liquidators hereby notify shareholders that due to ongoing investigations into the current affairs of the Company by the joint and several liquidators, the preparation of the financial statements for the year ended 31 December 2025 and the publication of the 2025 annual results has been delayed. Due to the delayed release of the 2025 annual results, it is expected that the 2025 annual report will also be delayed in its dispatch.
The Company will announce separately the publication dates for the 2025 annual results and the 2025 annual report in accordance with the Listing Rules.
Furthermore, trading in the Company's shares will remain suspended.
Related Articles

Shandong Lukang Pharmaceutical (600789.SH): The first subject has been enrolled in the phase IIb clinical trial of CMS203 tablets.

SIPAI HEALTH(00314): Ren Na appointed as authorized representative.

China Tourism Group Duty Free Corporation (01880) released its annual performance with a net profit attributable to shareholders of 3.644 billion yuan, a year-on-year decrease of 15.73%.
Shandong Lukang Pharmaceutical (600789.SH): The first subject has been enrolled in the phase IIb clinical trial of CMS203 tablets.

SIPAI HEALTH(00314): Ren Na appointed as authorized representative.

China Tourism Group Duty Free Corporation (01880) released its annual performance with a net profit attributable to shareholders of 3.644 billion yuan, a year-on-year decrease of 15.73%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


